Astrazeneca PLC (AZN) -0.63

Trade AZN
NOW!
Last Trade:44.11Short Ratio:4.20
Last Trade Time:4:00pmDay Range:44.00 - 44.56
Ask:Year Range:32.22 - 50.70
Bid:One Year Target:46.82
Open:44.51Exchange:NYSE
Volume:928461EBITDA:14.925B
Prev. Close:44.74Market Cap:64.004B
50 Day Moving:44.575Div Yield:5.14
200 day moving:45.503PE:8.62

Related RealMoney articles from TheStreet.com

Sanofi's Cancer Drug May Set New Standard
AstraZeneca Sees Bearish Move
Fitz Bits: Watch $59 in Pepsi

AstraZenca Wins Seroquel Trial (AZN)

Posted on 03/18/10 at 4:49pm
A New Jersey state court jury has ruled the Seroquel trial in AstraZenca Plc's (NYSE: AZN) favor. The plaintiff had held its antipsychotic drug Seroquel responsible for causing diabetes. The British company has about 10,400 lawsuits filed against it in U.S. courts. This case was the first one to reach the trial stage.
Click here to read the rest of the article
Posted in

New Jersey Court Rules in Astrazeneca's Favor on Seroquel Trial (AZN)

Posted on 03/18/10 at 11:18am
3/18/2010-Dow Jones reported Thursday that a jury in a New Jersey state court rejected a Louisiana plaintiff's claims that Astrazeneca's (NYSE: AZN) blockbuster antipsychotic drug Seroquel caused diabetes.
Click here to read the rest of the article

FDA to Ease Way for Multidrug Regimens (MRK,AZN)

Posted on 03/18/10 at 7:03am
3/18/2010-The Food and Drug Administration is devising guidelines that could accelerate testing and approval of multidrug regimens for some of the world's most deadly diseases, The Wall Street Journal reported.
Click here to read the rest of the article

Hot Stock Movers On FDA's Decision (MDT, CHTP, ACUR, AZN, MDCO)

Posted on 03/17/10 at 3:00am
(EMAILWIRE.COM, March 17, 2010 ) Dallas, Tx - Medtronic, Inc. (NYSE:MDT) fell 0.60% to $44.87 after hitting an intraday high of $45.24 after today announced it has completed Pre-Market Approval (PMA) submission in consideration for U.S.
Click here to read the rest of the article

New PLATO Sub-Analysis of CABG Patients Presented at ACC

Posted on 03/16/10 at 11:30am
New PLATO Sub-Analysis of CABG Patients Presented at ACC In this study, 48% fewer deaths reported among heart bypass patients taking ticagrelor (BRILINTA™/BRILIQUE™) as compared to clopidogrel PR Newswire ATLANTA, March 16
Click here to read the rest of the article

AstraZeneca Downward Momentum Looks to Continue (AZN)

Posted on 03/15/10 at 12:45pm
SmarTrend identified a Downtrend for AstraZeneca (NYSE: AZN) on January 28, 2010 at $47.22. In approximately 1 month, AstraZeneca has returned 6.6% as of today's recent price of $44.09.
Click here to read the rest of the article

AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma

Posted on 03/11/10 at 6:06pm
AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma PR Newswire WILMINGTON, Del., March 11
Click here to read the rest of the article

Kay Bross Named Program Director, Member & Vendor Relations, SAFE-BioPharma Association

Posted on 03/09/10 at 12:15pm
FT. LEE, N.J.--(BUSINESS WIRE)-- Kay Bross has been named Program Director, Member and Vendor Relations for SAFE-BioPharma Association, the non-profit association that created and manages the SAFE-BioPharma® digital identity and digital signature standard for the pharmaceutical and healthcare industries.
Click here to read the rest of the article